Ocular risk factors for recurrence of myopic choroidal neovascularization: Long-term follow-up study

Retina

Volumn 33, Issue 8, 2013, Pages 1613-1622

  Kang, Hae Min ^a   Koh, Hyoung Jun ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

antivascular endothelial growth factor injection; myopic choroidal neovascularization; photodynamic therapy; recurrence

Indexed keywords

VASCULOTROPIN INHIBITOR; VERTEPORFIN;

ADULT; ARTICLE; DISEASE ASSOCIATION; EYE AXIS LENGTH; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOPIC CHOROIDAL NEOVASCULARIZATION; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; RECURRENT DISEASE; REFRACTION ERROR; RETINA MACULA DEGENERATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION;

ADULT; ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; PHOTOCHEMOTHERAPY; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84883741007     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318285cc24     Document Type: Article

References (48)

1. Ghafour IM, Allan D, Foulds WS. Common causes of blindness and visual handicap in the west of Scotland. Br J Ophthalmol 1983;67:209-213.
2. Iwase A, Araie M, Tomidokoro A, et al. Prevalence and causes of low vision and blindness in a Japanese adult population: the Tajimi Study. Ophthalmology 2006;113:1354-1362.
3. Cotter SA, Varma R, Ying-Lai M, et al. Causes of low vision and blindness in adult Latinos: the Los Angeles Latino Eye Study. Ophthalmology 2006;113:1574-1582.
4. Lin LL, Shih YF, Hisao CK, Chen CJ. Prevalence of myopia in Taiwanese schoolchildren: 1983 to 2000. Ann Acad Med Singapore 2004;33:27-33.
5. Wong TY, Foster PJ, Hee J, et al. Prevalence and risk factors for refractive errors in adult Chinese in Singapore. Invest Ophthalmol Vis Sci 2000;41:2486-2494.
6. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991;7:403-422.
7. Wang Q, Klein BE, Klein R, Moss SE. Refractive status in the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci 1994;35: 4344-4347.
8. Attebo K, Ivers RQ, Mitchell P. Refractive errors in an older population: the Blue Mountains Eye Study. Ophthalmology 1999;106:1066-1072.
9. Grossniklaus HE, Green WR. Pathologic findings in pathologic myopia. Retina 1992;12:127-133.
10. Curtin BJ. Physiologic vs pathologic myopia: genetics vs environment. Ophthalmology 1979;86:681-691.
11. Steidl SM, Pruett RC. Macular complications associated with posterior staphyloma. Am J Ophthalmol 1997;123:181-187.
12. Curtin BJ. Ocular findings and complications. In: Curtain BJ, ed. The Myopias. Philadelphia, PA: Harper & Row; 1985:277-347.
13. Rabb MF, Garron I, LaFranco FP. Myopic macular degeneration. Int Ophthalmol Clin 1981;21:51-69.
14. Avila MP, Weiter JJ, Jalkh AE, et al. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984;91:1573-1581.
15. Fried M, Siebert A, Meyer-Schwickerath G. A natural history of Fuchs' spot: a long-term follow-up study. Doc Ophthalmol 1981;28:215-221.
16. Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983;90:923-926.
17. Curtin BJ, Karlin DB. Axial length measurements and fundus changes in the myopic eye. Am J Ophthalmol 1971;71:42-50.
18. Ohno-Matsui K, Yoshida T, Futagami S, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularization in pathological myopia. Br J Ophthalmol 2003;87:570-573.
19. Neelam K, Cheung CM, Ohno-Matsui K, et al. Choroidal neovascularization in pathologic myopia. Prog Retin Eye Res 2012;31: 495-525.
20. Sickenberg M, Schmidt-Erfurth U,Miller JW, et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch Ophthalmol 2000;118:327-336.
21. Blach RK. Degenerative myopia. In: Krill AE, Archer DB, eds. Krill's Hereditary Retinal and Choroidal Diseases. Vol. 2. Hagerstown, MD: Harper & Row; 1977:911-937.
22. Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choridal neovascularization: a 10-year follow-up. Ophthalmology 2003; 110:1297-1305.
23. Yoshida T, Ohno-Matsui K, Ohtake Y, et al. Long-term visual prognosis of choroidal neovascularization in highmyopia: a comparison between age groups. Ophthalmology 2002;109:712-719.
24. Kim YM, Yoon JU, Koh HJ. The analysis of lacquer crack in the assessment of myopic choroidal neovascularization. Eye 2011;25:937-946.
25. Silva RM, Ruiz-Moreno JM, Rosa P, et al. Intravitreal ranibizumab for myopic choroidal neovascularization 12-month results. Retina 2010;30:407-412.
26. Lai TY, Chan WM, Liu DT, Lam DS. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 2009;20:750-756.
27. Chen CH, Wu PC, Chen YJ, et al. Intravitreal injection of 2.5mg bevacizumab for treatment of myopic choroidal neovascularization in treatment-naive cases: a 2-year follow-up. J Ocul Pharmacol Ther 2011;27:295-400.
28. Hayashi K, Shimada N, Moriyama M, et al. Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopia. Retina 2012;32:687-695.
29. Holladay JT. Proper method for calculating average visual acuity. J Refract Surg 1997;13:388-391.
30. Treatment of Age-related macular degeneration with Photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol 1999;117: 1329-1345.
31. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in agerelated macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic cho-roidal neovascularizatioin-Verteporfin in Photodynamic Therapy Report 2. Am J Ophthalmol 2001;131:541-560.
32. Levy JH, Pollock HM, Curtin BJ. The Fuchs' spot: an ophthalmoscopic and fluorescein angiographic study. Ann Ophthalmol 1977;9:1433-1443.
33. Chan WM, Ohji M, Lai TY, et al. Choroidal neovascularization in pathological myopia: an update in management. Br J Ophthalmol 2005;89:1522-1528.
34. Grossniklaus HE, Gass JDM. Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes. Am J Ophthalmol 1998;126: 59-69.
35. Lopez PF, Lambert HM, Grossniklaus HE, Sternberg P. Well-defined subfoveal choroidal neovascular membranes in age-related macular degeneration. Ophthalmology 1993;100: 15-42.
36. Grossniklaus HE, Hutchinson AK, Capone A, et al. Clinicopathologic features of surgically excised choroidal vascular membranes. Ophthalmology 1994;101:1099-1111.
37. Gass JDM. Biomicroscopic and histologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Am J Ophthalmol 1994;118:285-298.
38. Itagaki T, Ohkuma H, Kato N. Studies on experimental subretinal neovascularization: regression of new vessels. Nippon Ganka Gakkai Zashi 1985;89:941-948.
39. Miller H, Miller B, Ryan SJ. The role of retinal pigment epithelium in the involution of subretinal neovascularization. Invest Ophthalmol Vis Sci 1986;27:1644-1652.
40. Glaser BM, Campochiaro PA, Davis JL Jr, Jerdan JA. Retinal pigment epithelial cells release inhibitors of neovascularization. Ophthalmology 1987;94:780-784.
41. Hayashi K, Ohno-Matsui K, Shimada N, et al. Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmology 2010;117:1595-1611.
42. Noble KG, Carr RE. Pathologic myopia. Ophthalmology 1982; 1099-1100.
43. Ikuno Y, Sayanagi K, Soga K, et al. Lacquer crack formation and choroidal neovascularization in pathologic myopia. Retina 2008;28:1124-1131.
44. Ruiz-Moreno JM, Montero JA. Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularization in highly myopic eyes. Br J Ophthalmol 2003;87:856-859.
45. Ohno-Matsui K, Yoshida T. Myopic choroidal neovascularization: natural course and treatment. Curr Opin Ophthalmol 2004;15:197-202.
46. Hayashi K, Ohno-Matsui K, Shimada N, et al. Long-term results of photodynamic therapy for choroidal neovascularization in Japanese patients with pathologic myopia. Am J Ophthalmol 2011;151:137-147.
47. Postelmans L, Pasteels B, Coquelet P, et al. Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. Am J Ophthalmol 2004;138:803-808.
48. Sii F, Lee LR. Retinopathy associated with photodynamic therapy for treatment of idiopathic choroidal neovascularization. Clin Experiment Ophthalmol 2006;34:184-186.